Wednesday, 8 April 2009
Crospon recognised for Technology Implementation by Frost & Sullivan Awards
2009 European Gastroenterology Technology Implementation of the Year Award
Crospon, a medical device developer based in Galway, Ireland has been recognised with the 2009 European Gastroenterology Technology Implementation of the Year Award by Frost & Sullivan.
The Award is in recognition of Crospon's successful implementation of the impedance planimetry technique for its EndoFLIP (endoscopic functional lumen imaging probe) imaging system. (www.endoflip.com)
Crospon has designed the EndoFLIP tool to provide a more physiologically relevant diagnostic test for gastroesophageal reflux disease (GERD). The EndoFLIP system also assists surgeons in the assessment of the degree of surgical tightening of the top of the stomach (sphincter region) during surgery.
Chronic GERD is a prevalent disorder reaching epidemic proportions worldwide that manifests itself as severe heartburn caused by the stomach acid refluxing up into the oesophagus.
'In cases of failure of GERD symptom control with targeted drugs, patients may be referred for minimally invasive surgical techniques as a remedy. However, the presently available arsenal of diagnostic tools are less effective in assessing the dysfunction of the valve, which gives rise to an urgent need for a clinically acceptable imaging platform that provides the most relevant information to diagnose GERD. Crospon Limited has remarkably addressed this critical need for a diagnostic platform targeting GERD by creating an integrated solution, called EndoFLIP, that facilitates real-time imaging of the lower oesophageal sphincter in less than 10 minutes', says Frost & Sullivan Global Research Manager Prasanna Vadhana Kannan.
In January, Crospon announced that its EndoFLIP system had received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish notified body in accordance with the European Medical Device Directive. CE Mark certification represented an important step in the company's development and ensures Crospon remains on schedule to release the EndoFLIP system into the European market by the end of the first half of 2009.
Commenting on the Frost & Sullivan recognition, John O'Dea, CEO Crospon said, 'We are in a critical phase of our development having recently established a US operation as we prepare for market entry. International recognition of the calibre of Frost & Sullivan is a significant boost for Crospon and our EndoFLIP system. '
'Apart from being equipped with the ease of deployment advantage, Crospon's EndoFLIP tool is also cost-effective, and the components of the imaging tool enable precise measurement of the distensibility and functional diameter of the sphincter region, thereby serving as an indispensable tool for the gastroenterologists,' comments Kannan.
The Frost & Sullivan Award for European Gastroenterology Technology implementation of the Year is conferred upon Crospon Limited for showcasing novel usage of endoscopic functional lumen imaging probe in accurately measuring the mechanical properties of the gastroesophageal junction.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Crospon formed in 2006, is a medical device company focused on the monitoring and treatment of gastroesophageal reflux disorder (GERD). Company co-founder and CEO, John O'Dea, previously cofounded Caradyne, a respiratory products company which was acquired by Respironics Inc in 2004.
Crospon recently won a Connaught Business Achievers Award for 2008 in the 'Ones to Watch' category and the company's Smart Drug Delivery Patch in conjunction with HP was listed in Popular Science's magazines annual 'Best of What's New' for 2008.